Manufacturing Samsung Biologics: geographic diversification is a sound business decision Pharmaceutical TechnologySamsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.Read full story pharminent July 22, 2026 (Last updated: July 23, 2026) Pharmaceutical Technology Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015. Read full story Post navigation Previous: Repligen builds in cell therapy with $1.5bn BioLife takeoverNext: Speciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing Related Stories Manufacturing Sandoz plans ‘vast and vertically integrated’ supply chain to support 100-biosimilar vision pharminent September 9, 2026 Manufacturing US puts $125m into personalised RNA therapy production pharminent September 2, 2026 Manufacturing Multispecifics are transforming the CDMO development architecture pharminent August 28, 2026